Halozyme Therapeutics, Inc. Share Price Today: Live Updates & Key Insights
Halozyme Therapeutics, Inc. share price today is $82, up 1.35%. The stock opened at $81.69 against the previous close of $80.84, with an intraday high of $82.7 and low of $81.04.
Halozyme Therapeutics, Inc. Share Price Chart
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. Share Price Performance
Halozyme Therapeutics, Inc. Institutional Holdings
Halozyme Therapeutics, Inc. Market Status
Halozyme Therapeutics, Inc. Fundamentals
Market Cap 9588.67 M
PB Ratio 42.0262
PE Ratio 27.3108
Enterprise Value 11056.48 M
Total Assets 2525.32 M
Volume 1661209
Halozyme Therapeutics, Inc. Company Financials
About Halozyme Therapeutics, Inc. & investment objective
Company Information Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Organisation Biotechnology
Employees 423
Industry Biotechnology
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Halozyme Therapeutics, Inc. FAQs
What is the share price of Halozyme Therapeutics, Inc. today?
The current share price of Halozyme Therapeutics, Inc. is $82.
Can I buy Halozyme Therapeutics, Inc. shares in India?
Yes, Indian investors can buy Halozyme Therapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.
How to buy Halozyme Therapeutics, Inc. shares in India?
You can easily invest in Halozyme Therapeutics, Inc. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Halozyme Therapeutics, Inc. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Halozyme Therapeutics, Inc..
Can I buy fractional shares of Halozyme Therapeutics, Inc.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. has a market cap of $9588.67 M.
In which sector does Halozyme Therapeutics, Inc. belong?
Halozyme Therapeutics, Inc. operates in the Biotechnology sector.
What documents are required to invest in Halozyme Therapeutics, Inc. stocks?
To invest, you typically need:
What is the PE and PB ratio of Halozyme Therapeutics, Inc.?
The PE ratio of Halozyme Therapeutics, Inc. is 27.31 and the PB ratio is 42.03.